{{Drugbox
| verifiedrevid = 437176910
| IUPAC_name = 1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl)butan-1-one
| image = Bunazosin.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|bunazosin}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number = 80755-51-7
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 2472
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2378
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9UUW4V7G2H
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 188185

<!--Chemical data-->
| chemical_formula =  
| C=19 | H=27 | N=5 | O=3 
| molecular_weight = 373.44 g/mol
| smiles = CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RHLJLALHBZGAFM-UHFFFAOYSA-N
}}

'''Bunazosin''' ([[International Nonproprietary Name|INN]]) is an [[alpha 1 antagonist]]. Bunazosin was initially developed to treat benign prostatic hyperplasia (BPH). It has been approved in Japan in a topical form to treat [[glaucoma]]. The mechanism of action is a reduction of aqueous outflow through the uveoscleral pathway resulting in lowering the intraocular pressure. It also may act to improve blood flow to the ocular nerve. Systemic Alpha-1 adrenergic receptor antagonists have been implicated in Intraoperative Floppy Iris Syndrome (IFIS). Bunazosin potentially could have the same effect but there has been no research to substantiate this as a risk for cataract surgery.

[[Category:Alpha blockers]]
[[Category:Phenol ethers]]
[[Category:Quinazolines]]
[[Category:Carboxamides]]
[[Category:Diazepanes]]


{{antihypertensive-stub}}